{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:51:41Z","timestamp":1788274301774,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00330-021-08305-x","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T05:03:14Z","timestamp":1632891794000},"page":"2200-2208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [18F]FDG PET\/CT volumetric parameters and tumour markers HE4 and CA125"],"prefix":"10.1007","volume":"32","author":[{"given":"Ariel","family":"Glickman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8097-9217","authenticated-orcid":false,"given":"Pilar","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Carreras-Di\u00e9guez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Ni\u00f1erola-Baiz\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Gaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Pahisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Fust\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"del Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"D\u00edaz-Feij\u00f3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Gonz\u00e1lez-Bosquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Agust\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"S\u00e1nchez-Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Perissinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Fern\u00e1ndez-Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Llu\u00eds","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Gil-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aureli","family":"Torn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"8305_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"8305_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/AOG.0000000000000917","volume":"126","author":"J Prat","year":"2015","unstructured":"Prat J (2015) Staging Classification for cancer of the ovary, fallopian tube, and peritoneum. Obstet Gynecol 126:171\u2013174. https:\/\/doi.org\/10.1097\/AOG.0000000000000917","journal-title":"Obstet Gynecol"},{"key":"8305_CR3","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943\u2013953. https:\/\/doi.org\/10.1056\/NEJMoa0908806","journal-title":"N Engl J Med"},{"key":"8305_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz062","author":"N Colombo","year":"2019","unstructured":"Colombo N, Sessa C, Du Bois A et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdz062","journal-title":"Ann Oncol"},{"key":"8305_CR5","doi-asserted-by":"publisher","first-page":"178.e1","DOI":"10.1016\/j.ajog.2009.10.856","volume":"202","author":"E Ch\u00e9reau","year":"2010","unstructured":"Ch\u00e9reau E, Ballester M, Selle F et al (2010) Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. Am J Obstet Gynecol 202:178.e1-178.e10. https:\/\/doi.org\/10.1016\/j.ajog.2009.10.856","journal-title":"Am J Obstet Gynecol"},{"key":"8305_CR6","doi-asserted-by":"publisher","unstructured":"Pignata S, Cannella L, Leopardo D et al (2011) Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Ann Oncol 22:viii40\u2013viii44. https:\/\/doi.org\/10.1093\/annonc\/mdr470","DOI":"10.1093\/annonc\/mdr470"},{"key":"8305_CR7","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/ijgc-2019-000211","volume":"29","author":"F Plotti","year":"2019","unstructured":"Plotti F, Guzzo F, Schir\u00f2 T et al (2019) Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients. Int J Gynecol Cancer 29:768\u2013771. https:\/\/doi.org\/10.1136\/ijgc-2019-000211","journal-title":"Int J Gynecol Cancer"},{"key":"8305_CR8","doi-asserted-by":"publisher","unstructured":"Zwakman N, van de Laar R, Van Gorp T et al (2017) Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer. J Gynecol Oncol 28: https:\/\/doi.org\/10.3802\/jgo.2017.28.e7","DOI":"10.3802\/jgo.2017.28.e7"},{"key":"8305_CR9","unstructured":"Simmons AR, Baggerly K, Bast RC (2013) The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park) 27(6):548\u201356"},{"key":"8305_CR10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.semnuclmed.2019.06.010","volume":"49","author":"J Kemppainen","year":"2019","unstructured":"Kemppainen J, Hynninen J, Virtanen J, Sepp\u00e4nen M (2019) PET\/CT for evaluation of ovarian cancer. Semin Nucl Med 49:484\u2013492. https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.06.010","journal-title":"Semin Nucl Med"},{"key":"8305_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejrad.2017.05.036","volume":"93","author":"R Gallicchio","year":"2017","unstructured":"Gallicchio R, Nardelli A, Venetucci A et al (2017) F-18 FDG PET\/CT metabolic tumor volume predicts overall survival in patients with disseminated epithelial ovarian cancer. Eur J Radiol 93:107\u2013113. https:\/\/doi.org\/10.1016\/j.ejrad.2017.05.036","journal-title":"Eur J Radiol"},{"key":"8305_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1157\/13073787","volume":"24","author":"G Ruiz-Hern\u00e1ndez","year":"2005","unstructured":"Ruiz-Hern\u00e1ndez G, Delgado-Bolton RC, Fern\u00e1ndez-P\u00e9rez C et al (2005) Meta-analysis of the diagnostic efficacy of FDG-PET in patients with suspected ovarian cancer recurrence.\u00a0Rev Esp Med Nucl\u00a024:161\u2013173. https:\/\/doi.org\/10.1157\/13073787","journal-title":"Rev Esp Med Nucl"},{"key":"8305_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1157\/13071687","volume":"24","author":"G Ruiz-Hern\u00e1ndez","year":"2005","unstructured":"Ruiz-Hern\u00e1ndez G, Delgado-Bolton RC, Fern\u00e1ndez-P\u00e9rez C et al (2005) Impact of positron emission tomography with FDG-PET in treatment of patients with suspected recurrent ovarian cancer. Rev Esp Med Nucl 24:113\u2013126. https:\/\/doi.org\/10.1157\/13071687","journal-title":"Rev Esp Med Nucl"},{"key":"8305_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.crad.2018.03.009","volume":"73","author":"H An","year":"2018","unstructured":"An H, Lee EYP, Chiu K, Chang C (2018) The emerging roles of functional imaging in ovarian cancer with peritoneal carcinomatosis. Clin Radiol 73:597\u2013609. https:\/\/doi.org\/10.1016\/j.crad.2018.03.009","journal-title":"Clin Radiol"},{"key":"8305_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4103\/wjnm.WJNM_31_17","volume":"16","author":"S Suppiah","year":"2017","unstructured":"Suppiah S, Chang WL, Hassan HA et al (2017) Systematic review on the accuracy of positron emission tomography\/computed tomography and positron emission tomography\/magnetic resonance imaging in the management of ovarian cancer: is functional information really needed? World J Nucl Med 16:176\u2013185","journal-title":"World J Nucl Med"},{"key":"8305_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/cbm-190904","volume":"27","author":"P Hogendorf","year":"2019","unstructured":"Hogendorf P, Durczy\u0144ski A, Skulimowski A, Kumor A, Pozna\u0144ska G, Strzelczyk J (2019) The role of 18F-FDG PET\/CT-based quantitative metabolic parameters in patients with ovarian clear cell carcinoma. Cancer Biomark 27:1\u20136. https:\/\/doi.org\/10.3233\/cbm-190904","journal-title":"Cancer Biomark"},{"key":"8305_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/ijgc-2019-000778","volume":"30","author":"MZ Muallem","year":"2020","unstructured":"Muallem MZ, Sehouli J, Richter R et al (2020) Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer. Int J Gynecol Cancer 30:62\u201366. https:\/\/doi.org\/10.1136\/ijgc-2019-000778","journal-title":"Int J Gynecol Cancer"},{"key":"8305_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5152\/jtgga.2015.15251","volume":"16","author":"L Evangelista","year":"2015","unstructured":"Evangelista L, Palma MD, Gregianin M et al (2015) Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography\/ computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients. J Turk Ger Gynecol Assoc 16:137\u2013144. https:\/\/doi.org\/10.5152\/jtgga.2015.15251","journal-title":"J Turk Ger Gynecol Assoc"},{"key":"8305_CR19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG et al (2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328\u2013354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8305_CR20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s12149-018-1289-1","volume":"32","author":"S Han","year":"2018","unstructured":"Han S, Suh CH, Kim YJ et al (2018) Prognostic value of volume-based metabolic parameters of 18F-FDG PET\/CT in ovarian cancer: a systematic review and meta-analysis. Ann Nucl Med 32:669\u2013677. https:\/\/doi.org\/10.1007\/s12149-018-1289-1","journal-title":"Ann Nucl Med"},{"key":"8305_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s13402-020-00513-9","volume":"43","author":"M Yousefi","year":"2020","unstructured":"Yousefi M, Dehghani S, Nosrati R et al (2020) Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles. Cell Oncol 43:515\u2013538. https:\/\/doi.org\/10.1007\/s13402-020-00513-9","journal-title":"Cell Oncol"},{"key":"8305_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/jso.21484","volume":"101","author":"PH Sugarbaker","year":"2010","unstructured":"Sugarbaker PH (2010) Surgical responsibilities in the management of peritoneal carcinomatosis. J Surg Oncol 101:713\u2013724. https:\/\/doi.org\/10.1002\/jso.21484","journal-title":"J Surg Oncol"},{"key":"8305_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3802\/jgo.2012.23.1.28","volume":"23","author":"HH Chung","year":"2012","unstructured":"Chung HH, Kwon HW, Kang KW et al (2012) Preoperative [18 F]FDG PET\/CT predicts recurrence in patients with epithelial ovarian cancer. J Gynecol Oncol 23:28. https:\/\/doi.org\/10.3802\/jgo.2012.23.1.28","journal-title":"J Gynecol Oncol"},{"key":"8305_CR24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/cas.12890","volume":"107","author":"M Yamamoto","year":"2016","unstructured":"Yamamoto M, Tsujikawa T, Fujita Y et al (2016) Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy. Cancer Sci 107:478\u2013485. https:\/\/doi.org\/10.1111\/cas.12890","journal-title":"Cancer Sci"},{"key":"8305_CR25","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1007\/s00259-014-2803-x","volume":"41","author":"JW Lee","year":"2014","unstructured":"Lee JW, Cho A, Lee J-H et al (2014) The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET\/CT in the prognosis of epithelial ovarian cancer. Eur J Nucl Med Mol Imaging 41:1898\u20131906. https:\/\/doi.org\/10.1007\/s00259-014-2803-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8305_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.remn.2015.08.005","volume":"35","author":"M Mayoral","year":"2016","unstructured":"Mayoral M, Fernandez-Martinez A, Vidal L et al (2016) Prognostic value of 18F-FDG PET\/CT volumetric parameters in recurrent epithelial ovarian cancer. Rev Esp Med Nucl Imagen Mol 35:88\u201395. https:\/\/doi.org\/10.1016\/j.remn.2015.08.005","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"8305_CR27","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ygyno.2014.12.032","volume":"136","author":"C-Y Kim","year":"2015","unstructured":"Kim C-Y, Jeong SY, Chong GO et al (2015) Quantitative metabolic parameters measured on F-18 FDG PET\/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. Gynecol Oncol 136:498\u2013504. https:\/\/doi.org\/10.1016\/j.ygyno.2014.12.032","journal-title":"Gynecol Oncol"},{"key":"8305_CR28","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/IGC.0000000000000944","volume":"27","author":"F Plotti","year":"2017","unstructured":"Plotti F, Scaletta G, Capriglione S et al (2017) The role of HE4, a novel biomarker, in predicting optimal cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer 27:696\u2013702. https:\/\/doi.org\/10.1097\/IGC.0000000000000944","journal-title":"Int J Gynecol Cancer"},{"key":"8305_CR29","doi-asserted-by":"publisher","first-page":"14765","DOI":"10.1007\/s13277-016-5335-0","volume":"37","author":"Y Shen","year":"2016","unstructured":"Shen Y, Li L (2016) Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer. Tumor Biol 37:14765\u201314772. https:\/\/doi.org\/10.1007\/s13277-016-5335-0","journal-title":"Tumor Biol"},{"key":"8305_CR30","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/RLI.0000000000000050","volume":"49","author":"T Tsuboyama","year":"2014","unstructured":"Tsuboyama T, Tatsumi M, Onishi H et al (2014) Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography\/computed tomography for evaluation of ovarian masses. Invest Radiol 49:524\u2013531. https:\/\/doi.org\/10.1097\/RLI.0000000000000050","journal-title":"Invest Radiol"},{"key":"8305_CR31","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1097\/IGC.0000000000000180","volume":"24","author":"H Konishi","year":"2014","unstructured":"Konishi H, Takehara K, Kojima A et al (2014) Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography\/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 24:1190\u20131194. https:\/\/doi.org\/10.1097\/IGC.0000000000000180","journal-title":"Int J Gynecol Cancer"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-021-08305-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-021-08305-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-021-08305-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T17:27:44Z","timestamp":1647278864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-021-08305-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["8305"],"URL":"https:\/\/doi.org\/10.1007\/s00330-021-08305-x","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"21 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Aureli Torn\u00e9.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 retrospective\u2022 cross sectional study\u2022 observational\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}